J. Liebmann

1.3k total citations
19 papers, 1.2k citations indexed

About

J. Liebmann is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, J. Liebmann has authored 19 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 4 papers in Molecular Biology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in J. Liebmann's work include Cancer Treatment and Pharmacology (11 papers), Lung Cancer Treatments and Mutations (4 papers) and Colorectal Cancer Treatments and Studies (3 papers). J. Liebmann is often cited by papers focused on Cancer Treatment and Pharmacology (11 papers), Lung Cancer Treatments and Mutations (4 papers) and Colorectal Cancer Treatments and Studies (3 papers). J. Liebmann collaborates with scholars based in United States and Germany. J. Liebmann's co-authors include J A Cook, Diane Teague, Joyce M. Fisher, Claudia A. Lipschultz, Joseph B. Fisher, David C. Kaufman, David A. Wink, James B. Mitchell, S.M. Hahn and James B. Mitchell and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Journal of Agricultural and Food Chemistry.

In The Last Decade

J. Liebmann

19 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J. Liebmann United States	14	548	324	218	134	121	19	1.2k
Diane Teague United States	12	579 1.1×	317 1.0×	206 0.9×	136 1.0×	103 0.9×	14	1.1k
Marie-Christine Bissery France	17	724 1.3×	432 1.3×	164 0.8×	173 1.3×	51 0.4×	23	1.2k
M. Bayssas France	17	1.3k 2.3×	503 1.6×	188 0.9×	191 1.4×	121 1.0×	34	1.8k
Joyce M. Fisher United States	19	586 1.1×	713 2.2×	121 0.6×	115 0.9×	66 0.5×	36	1.5k
Lorraine A. Cazenave United States	6	847 1.5×	558 1.7×	102 0.5×	95 0.7×	94 0.8×	7	1.3k
Willem J. Nooijen Netherlands	14	1.1k 2.1×	343 1.1×	179 0.8×	174 1.3×	95 0.8×	21	1.6k
Marie-Christine Bissery France	17	641 1.2×	641 2.0×	209 1.0×	184 1.4×	52 0.4×	41	1.4k
Jun Ho Yi South Korea	22	552 1.0×	514 1.6×	214 1.0×	324 2.4×	163 1.3×	88	1.5k
Feng Luo United States	22	552 1.0×	496 1.5×	142 0.7×	102 0.8×	58 0.5×	36	1.3k
Mario D’Andrea Italy	18	1.2k 2.2×	857 2.6×	231 1.1×	230 1.7×	162 1.3×	54	1.8k

Countries citing papers authored by J. Liebmann

Since Specialization

Citations

This map shows the geographic impact of J. Liebmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Liebmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Liebmann more than expected).

Fields of papers citing papers by J. Liebmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Liebmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Liebmann. The network helps show where J. Liebmann may publish in the future.

Co-authorship network of co-authors of J. Liebmann

This figure shows the co-authorship network connecting the top 25 collaborators of J. Liebmann. A scholar is included among the top collaborators of J. Liebmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Liebmann. J. Liebmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

1.

Moll, Solange, et al.. (2006). Thalidomide increases thrombin generation in multiple myeloma patients. Journal of Clinical Oncology. 24(18_suppl). 7602–7602. 1 indexed citations

2.

Henderson, I. Craig, David R. Spigel, John Nemunaitis, et al.. (2006). A phase 1 study of weekly, divided dose perifosine in patients (pts) with non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 24(18_suppl). 13063–13063. 4 indexed citations

3.

Patt, Yehuda Z., J. Liebmann, Sabine Eckhardt, et al.. (2004). Capecitabine (X) plus irinotecan (XELIRI) as first-line treatment for metastatic colorectal cancer (MCRC): Final safety findings from a phase II trial. Journal of Clinical Oncology. 22(14_suppl). 3602–3602. 3 indexed citations

4.

Patt, Yehuda Z., J. Liebmann, Sabine Eckhardt, et al.. (2004). Capecitabine (X) plus irinotecan (XELIRI) as first-line treatment for metastatic colorectal cancer (MCRC): Final safety findings from a phase II trial. Journal of Clinical Oncology. 22(14_suppl). 3602–3602. 25 indexed citations

5.

Herscher, Laurie L., S.M. Hahn, Glenn S. Kroog, et al.. (1998). Phase I study of paclitaxel as a radiation sensitizer in the treatment of mesothelioma and non-small-cell lung cancer.. Journal of Clinical Oncology. 16(2). 635–641. 31 indexed citations

6.

Wink, David A., Yoram Vodovotz, Jonathan Cook, et al.. (1998). The role of nitric oxide chemistry in cancer treatment.. PubMed. 63(7). 802–9. 64 indexed citations

7.

Cook, J A, Joyce M. Fisher, Diane Teague, et al.. (1998). Interaction of gemcitabine with paclitaxel and cisplatin in human tumor cell lines.. International Journal of Oncology. 12(4). 825–32. 55 indexed citations

8.

Schulz, Hartwig, et al.. (1998). Distribution of Volatile Sulfur Compounds in an Interspecific Hybrid between Onion (Allium cepa L.) and Leek (Allium porrum L.). Journal of Agricultural and Food Chemistry. 46(12). 5220–5224. 36 indexed citations

9.

Cook, J A, Roberto Pacelli, William DeGraff, et al.. (1997). Nitric oxide enhancement of melphalan-induced cytotoxicity. British Journal of Cancer. 76(3). 325–334. 34 indexed citations

10.

Liebmann, J., et al.. (1996). Antagonism of paclitaxel cytotoxicity by X-rays. International Journal of Oncology. 8(5). 991–6. 13 indexed citations

11.

Liebmann, J., et al.. (1995). Radiation reaction recall following simvastatin therapy: A new observation. Clinical Oncology. 7(5). 325–326. 70 indexed citations

12.

Liebmann, J., et al.. (1995). Enhanced glutathione peroxidase expression protects cells from hydroperoxides but not from radiation or doxorubicin.. PubMed. 55(19). 4465–70. 28 indexed citations

13.

Liebmann, J., Joyce M. Fisher, Diane Teague, & J A Cook. (1994). Sequence dependence of paclitaxel (Taxol) combined with cisplatin or alkylators in human cancer cells.. PubMed. 6(1). 25–31. 48 indexed citations

14.

Liebmann, J., et al.. (1994). In Vitro Studies of Taxol as a Radiation Sensitizer in Human Tumor Cells. JNCI Journal of the National Cancer Institute. 86(6). 441–446. 241 indexed citations

15.

Liebmann, J., et al.. (1994). [Methanol formation in vitro and in vivo (methanol formation after pectin administration)].. PubMed. 31(4). 228–32. 7 indexed citations

16.

Liebmann, J., Anne Marie DeLuca, Deborah Coffin, et al.. (1994). In vivo radiation protection by nitric oxide modulation.. PubMed. 54(13). 3365–8. 51 indexed citations

17.

Liebmann, J., et al.. (1994). ZUR METHANOLBILDUNG IN VITRO UND VIVO (METHANOLBILDUNG NACH PEKTINGABEN). 31(4). 2 indexed citations

18.

Liebmann, J., et al.. (1993). Cytotoxic studies of paclitaxel (Taxol®) in human tumour cell lines. British Journal of Cancer. 68(6). 1104–1109. 376 indexed citations

19.

Liebmann, J., S.M. Hahn, John Cook, et al.. (1993). Glutathione depletion by L-buthionine sulfoximine antagonizes taxol cytotoxicity.. PubMed. 53(9). 2066–70. 77 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact